489 related articles for article (PubMed ID: 27653507)
21. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
22. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
Carvalho R; Maio P; Cunha D; Freitas I; Afonso A; Cardoso J
Eur J Dermatol; 2011; 21(3):415-6. PubMed ID: 21527367
[No Abstract] [Full Text] [Related]
23. Correlation of anti-γ/ε nicotinic acetylcholine receptor antibody levels with anti-desmoglein 1,3 antibody levels and disease severity in pemphigus vulgaris.
Toosi R; Teymourzadeh A; Mahmoudi H; Balighi K; Daneshpazhooh M
Clin Exp Dermatol; 2021 Oct; 46(7):1230-1235. PubMed ID: 33713456
[TBL] [Abstract][Full Text] [Related]
24. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
25. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus.
Lakshmi MJD; Jaisankar TJ; Rajappa M; Thappa DM; Chandrashekar L; Divyapriya D; Munisamy M; Revathy G
J Am Acad Dermatol; 2017 May; 76(5):895-902. PubMed ID: 28089115
[TBL] [Abstract][Full Text] [Related]
26. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
[TBL] [Abstract][Full Text] [Related]
27. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).
Dupuy A; Viguier M; Bédane C; Cordoliani F; Blaise S; Aucouturier F; Bonnetblanc JM; Morel P; Dubertret L; Bachelez H
Arch Dermatol; 2004 Jan; 140(1):91-6. PubMed ID: 14732665
[TBL] [Abstract][Full Text] [Related]
28. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of rituximab in patients with severe pemphigus.
Schmidt E; Hennig K; Mengede C; Zillikens D; Kromminga A
Clin Immunol; 2009 Sep; 132(3):334-41. PubMed ID: 19502112
[TBL] [Abstract][Full Text] [Related]
30. A single cycle of rituximab for the treatment of severe pemphigus.
Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
[TBL] [Abstract][Full Text] [Related]
32. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.
Hammers CM; Chen J; Lin C; Kacir S; Siegel DL; Payne AS; Stanley JR
J Invest Dermatol; 2015 Mar; 135(3):742-749. PubMed ID: 25142730
[TBL] [Abstract][Full Text] [Related]
33. Pemphigus: Current and Future Therapeutic Strategies.
Didona D; Maglie R; Eming R; Hertl M
Front Immunol; 2019; 10():1418. PubMed ID: 31293582
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
35. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab.
Balighi K; Sakhi RS; Daneshpazhooh M; Mahmoudi H; Teimourpour A; Tavakolpour S
Dermatol Ther; 2018 Nov; 31(6):e12671. PubMed ID: 30246907
[No Abstract] [Full Text] [Related]
36. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Tracking of Autoantibody Levels in a Pemphigus Vulgaris Patient: Support for a Role of Anti-Desmoglein 1 Autoantibodies as Predictors of Disease Progression.
Abidi NY; Lainiotis I; Malikowski G; Seiffert-Sinha K; Sinha AA
J Drugs Dermatol; 2017 Feb; 16(2):135-139. PubMed ID: 28300855
[TBL] [Abstract][Full Text] [Related]
38. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases.
Antonucci A; Negosanti M; Tabanelli M; Varotti C
J Dermatolog Treat; 2007; 18(3):178-83. PubMed ID: 17538808
[TBL] [Abstract][Full Text] [Related]
39. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
40. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
